Study of Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicle Eye Drops for Treating Dry Eye Disease

What this Trial Is About

Researchers are evaluating the safety and effectiveness of eye drops made from human umbilical cord mesenchymal stem cell small extracellular vesicles in adults with dry eye disease. This early-phase clinical trial focuses on patients who have a history of dry eye disease with specific symptoms and clinical signs, aiming to understand how these eye drops may help relieve their condition. Participants will receive one drop of these stem cell-derived eye drops four times a day for four weeks. During this treatment period, they will visit the clinic weekly for examinations and tests. After completing treatment, follow-up visits will occur every two weeks for two visits, followed by longer-term follow-ups at three and six months to observe sustained safety and potential benefits. Throughout the study, participants will record their medication use and any side effects. Researchers will assess eye health using measures such as the Total Corneal Fluorescein Staining Score and Tear Film Break-up Time at four weeks. Safety and effectiveness will be monitored closely during treatment and follow-up visits, with the total participation spanning over six months to gather long-term data.

Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease